Maria Lourdes Garza-Rodríguez

Prof. Dr. Maria Lourdes Garza-Rodríguez

Oncology Service, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Nuevo León, Mexico
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2013 in Nature
Verified
Journal Article
Closed access
PDF file
AOAkinyemi I. Ojesina
Akinyemi I. Ojesina
LLLee Lichtenstein
Lee Lichtenstein
SFSamuel S. Freeman
Samuel S. Freeman
CPChandra Sekhar Pedamallu
Chandra Sekhar Pedamallu
IIIvan Imaz-Rosshandler
Ivan Imaz-Rosshandler
MMMatthew Meyerson
Matthew Meyerson

1 July 2018 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
Mariel Araceli Oyervides-MuñozMariel Araceli Oyervides-Muñoz
Mariel Araceli Oyervides-Muñoz
Antonio Ali Perez-MayaAntonio Ali Perez-Maya
Antonio Ali Perez-Maya
HRHazyadee Frecia Rodríguez-Gutiérrez
Hazyadee Frecia Rodríguez-Gutiérrez
GGGabriela Sofía Gómez-Macias
Gabriela Sofía Gómez-Macias
OFOscar Raúl Fajardo-Ramírez
Oscar Raúl Fajardo-Ramírez
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez

31 March 2020 in Viruses
Verified
Journal Article
Open access
PDF file
Mariel Araceli Oyervides-MuñozMariel Araceli Oyervides-Muñoz
Mariel Araceli Oyervides-Muñoz
Antonio Ali Perez-MayaAntonio Ali Perez-Maya
Antonio Ali Perez-Maya
Celia N Sánchez-DomínguezCelia N Sánchez-Domínguez
Celia N Sánchez-Domínguez
ABAnais Berlanga
Anais Berlanga
MAMauro Antonio-Macedo
Mauro Antonio-Macedo
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
Persistent high-risk human papillomavirus (HR-HPV) infections play a major role in the development of invasive cervical cancer (CC), and screening for such infections is in many countries the primary method of detecting and preventing CC. HPV typing can be used for triage and risk stratification of women with atypical squamous cells of undetermined significance (ASC-US)/low-grade cervical lesions (LSIL), though the current clinical practice in Mexico is to diagnose CC or its preceding conditions mainly via histology and HR-HPV detection. Additional information regarding these HPV infections, such as viral load and co-infecting agents, might also be useful for diagnosing, predicting, and evaluating the possible consequences of the infection and of its prevention by vaccination. The goal of this follow-up hospital case study was to determine if HPV types, multiple HPV infections, and viral loads were associated with infection persistence and the cervical lesion grade. A total of 294 cervical cytology samples drawn from patients with gynecological alterations were used in this study. HPV types were identified by real-time PCR DNA analysis. A subset of HPV-positive patients was reevaluated to identify persistent infections. We identified HPV types 16, 18, and 39 as the most prevalent. One hundred five of the patients (59%) were infected with more than one type of HPV. The types of HPV associated with multiple HPV infections were 16, 18, and 39. In the follow-up samples, 38% of patients had not cleared the initially detected HPV infection, and these were considered persistent. We found here an association between multiple HPV infections and high viral loads with and infection persistence. Our findings suggest there are benefits in ascertaining viral load and multiple HPV infections status of HR-HPV infections for predicting the risk of persistence, a requirement for developing CC. These findings contribute to our understanding of HPV epidemiology and may allow screening programs to better assess the cancer-developing risks associated with individual HR-HPV infections.

26 February 2019 in International Journal of Molecular Medicine
Verified
Journal Article
Open access
PDF file
DRDiana Raquel Rodríguez-Rodríguez
Diana Raquel Rodríguez-Rodríguez
RRRamiro Ramírez-Solís
Ramiro Ramírez-Solís
MGMario Alberto Garza-Elizondo
Mario Alberto Garza-Elizondo
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
HBHugo Alberto Barrera-Saldaña
Hugo Alberto Barrera-Saldaña
Genome editing reemerged in 2012 with the development of CRISPR/Cas9 technology, which is a genetic manipulation tool derived from the defense system of certain bacteria against viruses and plasmids. This method is easy to apply and has been used in a wide variety of experimental models, including cell lines, laboratory animals, plants, and even in human clinical trials. The CRISPR/Cas9 system consists of directing the Cas9 nuclease to create a site‑directed double‑strand DNA break using a small RNA molecule as a guide. A process that allows a permanent modification of the genomic target sequence can repair the damage caused to DNA. In the present study, the basic principles of the CRISPR/Cas9 system are reviewed, as well as the strategies and modifications of the enzyme Cas9 to eliminate the off‑target cuts, and the different applications of CRISPR/Cas9 as a system for visualization and gene expression activation or suppression. In addition, the review emphasizes on the potential application of this system in the treatment of different diseases, such as pulmonary, gastrointestinal, hematologic, immune system, viral, autoimmune and inflammatory diseases, and cancer.

19 January 2015 in Journal of Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
VICTOR TREVINOVICTOR TREVINO
VICTOR TREVINO
IYIrma‐Luz Yañez‐Garza
Irma‐Luz Yañez‐Garza
CRCarlos Rodríguez-López
Carlos Rodríguez-López
RURafael Urrea‐López
Rafael Urrea‐López
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
RDRocío‐Isabel Díaz De‐La‐Garza
Rocío‐Isabel Díaz De‐La‐Garza

1 April 2014 in Growth Hormone & IGF Research
Verified
Journal Article
Closed access
DPDiana Pérez
Diana Pérez
IRIram Pablo Rodríguez-Sánchez
Iram Pablo Rodríguez-Sánchez
Maria Lourdes Garza-RodríguezMaria Lourdes Garza-Rodríguez
Maria Lourdes Garza-Rodríguez
HBHugo A Barrera-Saldaña
Hugo A Barrera-Saldaña